1241 views5 min read
Halucenex Life Sciences Inc. targets Australian market following landmark TGA decision
The wholly-owned Creso Pharma subsidiary is currently conducting clinical trials of its synthetic psilocybin formulation as treatment for mental health conditionsNEDLANDS, Australia, Feb. 8, 2023 -- Creso Pharma Limited (ASX:CPH, FRA:1X8) ('Creso Pharma') is pleased to announce its wholly-owned psychedelics subsidiary, Halucenex Life Scie... Read More...